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Abstract
Introduction: Glycolysis affects glucose determination in vitro. The placement of sample tubes in ice-water slurry with plasma separation within 30 
minutes is recommended, or alternatively the use of a glycolysis inhibitor. The aim of our two-steps study was to evaluate which Terumo tube is best 
for glucose determination in routine clinical setting.
Materials and methods: In the first study, blood from 100 volunteers was collected into lithium heparin (LH), NaF/Na heparin (FH) and NaF/citrate 
buffer/Na2EDTA (FC-Mixture) tubes. LH sample was treated as recommended and considered as reference, while FH and FC-Mixture samples were 
aliquoted, maintained at room temperature (RT) for 1, 2 and 4 hours; centrifuged and plasma analysed in triplicate. In the second study, samples 
from 375 volunteers were collected in LH, FH and FC-Mixture tubes and held at RT before centrifugation from 10 to 340 minutes, depending on each 
laboratory practice. Samples were analysed in one analytical run.
Results: In the first study, FH glucose concentrations were 5.15 ± 0.66 mmol/L, 5.05 ± 0.65 mmol/L and 5.00 ± 0.65 mmol/L (P < 0.001) in tubes 
stored at RT for 1, 2 and 4 hours, respectively. Mean biases in all time points exceeded the analytical goal for desirable bias based on biological varia-
tion criteria. FC-Mixture glucose concentrations were 5.48 ± 0.65 mmol/L, 5.46 ± 0.6 mmol/L and 5.46 ± 0.64 mmol/L in tubes stored at RT for 1, 2 
and 4 hours, respectively. Mean biases for FC-Mixture glucose in all time points reached optimal analytical goals. In the second study, the biases for 
LH and FH glucose compared to reference FC-Mixture glucose exceeded the preset analytical goals, regardless of the blood collection to centrifuga-
tion time interval.
Conclusions: FC-mixture tubes glucose concentrations were preserved up to 4h storage at RT. We confirmed that NaF alone does not allow imme-
diate glycolysis inhibition in real life pre-centrifugation storage conditions (up to 340 minutes). FC-Mixture should be used exclusively for glucose 
determination in laboratories unable to implement the recommended blood samples’ treatment.
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Introduction
Laboratory plasma glucose testing is fundamental 
for the diagnosis of diabetes mellitus (DM), im-
paired fasting glucose (IFG) and/or impaired glu-
cose tolerance (IGT) and in particular for the 
screening and diagnosis of gestational diabetes 
mellitus (GDM) where HbA1c can’t be used (1-3). 
Therefore is evident that the plasma glucose meas-
urement needs to be accurate and precise for cor-
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rect patient classification according to the well-es-
tablished international guidelines (4).
The principally used analytical methods for glu-
cose determination are enzymatic assays, based 
on the hexokinase (recommended) or on the glu-
cose oxidase reaction (5). These methods are high-
ly standardized with an inter-laboratory impreci-
sion (CV) < 2.6% (1,4,5).
Thus, in glucose measurement, the analytical vari-
ation is highly reduced while it is the pre-analytical 
variation that is responsible for most of total varia-
tion in glucose determination (4,6). It has been re-
ported an in vitro decrease in plasma glucose sam-
ples, not immediately centrifuged, of 5 - 7% per 
hour due to glycolysis (7).
To minimize in vitro glycolysis, the American Dia-
betes Association (ADA) and the National Acade-
my of Clinical Biochemistry (NACB) recommend to 
immediately place the sample tube in ice-water 
slurry and to separate plasma from cells within 30 
minutes (8) and, if this is not possible, as in most 
Italian laboratories, to use a sample tube contain-
ing rapid glycolysis inhibitor (such as citrate buffer) 
(8). 
In order to perform this task, sodium fluoride (NaF) 
exerting its action on enolase, an enzyme which 
catalysed a down-stream step of glycolysis, played 
a fundamental role in the past. However, the inhib-
itory effect of NaF on glycolysis appears only after 
2-3 hours from blood collection, with the effect 
that the glucose concentration in this lapse of time 
decreases (5,7,9).
In the last years the use of blood-collection tubes 
with NaF and citrate buffer have been proposed: 
the acidification of blood below pH 5.9 inhibits the 
hexokinase and phosphofructokinase, enzymes 
involved in the up-stream steps of glycolysis, 
therefore ensuring a quicker inhibition of it (10,11).
Since the site of blood drawing is far from the cen-
tral laboratory for most of Italian laboratories (even 
hundreds of kilometres), which in turn prevents 
the implementation of ADA-NACB guidelines for 
sample treatment, the “Italian joint SIBioC-SIPMeL 
Study Group on Diabetes Mellitus” has performed 
a two-steps study using VenosafeTM tubes (Teru-
mo, Rome, Italy): 1) an experimental pilot project 
to evaluate the effect of different glycolysis inhibi-
tors on the stability of glycaemia in samples main-
tained at room temperature (RT) for 1, 2 and 4 
hours; and 2) a multi-centric study to verify how 
different real life conditions of blood collection 
(i.e. use of lithium-heparin or sodium fluoride as 
anticoagulants) and processing (i.e. time between 
blood collection and centrifugation) could influ-
ence plasma glucose determination.
Our hypothesis is that the use of an immediate 
glycolysis inhibitor has to be regarded as neces-
sary to perform a correct diagnosis or monitoring 
of DM.
Materials and methods
Experimental study 
Study population 
The study has been performed in the Clinical 
Chemistry Laboratory of Spedali Civili of Brescia 
between April 2013 and May 2014, following the 
ethical standards of the revised Declaration of Hel-
sinki. One hundred fasting and non-fasting volun-
teers (29 males, 71 females), median age 44 years 
(range: 18-75 years), recruited from the staff of the 
laboratories of Spedali Civili of Brescia and their 
relatives, have been subjected to venous blood 
collection from antecubital fossa of the arm be-
tween 9.00 a.m. and 2.00 p.m. by a single skilled 
phlebotomist through tubing 21 G*3/4’’ (Terumo, 
Rome, Italy, ref. MN*SV21) and holder (Terumo, 
Rome, Italy , ref. XX-VF010HGS).
Study design 
A total of 11 mL of blood was collected from each 
volunteer in three different VenosafeTM tubes (Ter-
umo, Rome, Italy):
1. Lithium heparin (LH) 4 mL draw (ref. VF-054SHL)
2. NaF/Na Heparin (FH) 4 mL draw (ref. VF-054SFH)
3. NaF/citrate buffer/Na2EDTA (FC-Mixture) 3 mL 
draw (ref. VF-053SFC32).
The LH sample was subjected to the ADA - NACB 
recommended gold-standard treatment (8): after 
blood collection it was immediately placed in ice-
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water slurry and centrifuged at 2500 x g for 15 
minutes at 4 °C using J6-MI centrifuge (Beckman 
Coulter, Milan, Italy). Plasma was finally separated 
from blood cells and kept in 1.5 mL tubes at 4 °C 
until analysis.
The FH and FC-Mixture whole blood samples were 
immediately separated after blood collection in 
three aliquots (1.3 mL of FH and 1 mL of FC-Mix-
ture whole blood sample, respectively) and kept in 
three 1.5 mL tubes placed at room temperature 
(20 - 25 °C). After a storage period of 1, 2 and 4 
hours, they were centrifuged at 2500 x g for 15 
minutes at 4 °C to obtain complete separation of 
plasma from blood cells. Plasma was then stored 
in 1.5 mL tubes at 4 °C until analysis.
Methods
Glucose testing of all samples of the same subject 
was performed in triplicate in the same analytical 
run, in order to reduce analytical variability (CV in-
tra-assay < 0.99%). Glucose concentrations were 
measured by hexokinase method on a Dimension 
Vista 1500 system (Siemens Healthcare Diagnos-
tics, Milan, Italy).
Multi-centre study
Study population 
The multi-centre study involved 15 Italian labora-
tories (Metabolic Diseases and Diabetology Unit-
INRCA-IRCCS, Ancona; Clinical Chemistry Labora-
tory, Spedali Civili of Brescia, Brescia; Clinical Labo-
ratory & Molecular Diagnostics, INRCA National In-
stitute, Ancona; Clinical Chemistry and Haematol-
ogy Laboratory, St. Bortolo Hospital, Vicenza; Lab-
oratory of Clinical Pathology, Hospital SS. Annun-
ziata, Chieti; Department of Clinical and Experi-
mental Medicine, University Hospital of Messina; 
Laboratory Medicine, Azienda ULSS No. 9, Treviso; 
Clinical Biochemistry Laboratory, Bracciano Hospi-
tal, Rome; Laboratory of Clinical Chemistry and 
Hematology, University Hospital of Parma, Parma; 
Clinical Laboratory, AOUI Verona, Verona; ASUR 8, 
Recanati, Macerata; Servizio di Medicina di labora-
torio, San Raffaele Scientific Institute, Milan; Raven-
na Spoke Laboratory, AUSL Romagna; Laboratory 
of Clinical Chemistry - Hospital Agency Pugliese, 
Ciaccio, Catanzaro; Department of Laboratory 
Medicine, University Hospital, Padova). Blood sam-
ples were collected from the antecubital vein of 
375 fasting and non-fasting volunteers (142 males 
and 233 females), aged 51 years (range: 18-91 
years), to cover a wide range of plasma glucose 
concentrations (2.44 - 25.17 mmol/L). To minimize 
venipuncture bias in each laboratory, all venipunc-
tures were performed by a single skilled phleboto-
mist.
Study design
A total of 11 mL of blood was collected from each 
volunteer in three different VenosafeTM LH, FH and 
FC-Mixture tubes (Terumo, Rome, Italy). Immedi-
ately after venipuncture the blood was thoroughly 
mixed with the anticoagulant by inverting the 
tubes several times, according to manufacturer’s 
recommendations (12). Sample tubes were kept at 
room temperature (variable from each laboratory 
from 15-25 °C) and then centrifuged.
The time from blood sample collection to centrifu-
gation was established by each laboratory and 
was recorded (between 10 and 340 minutes for all 
the samples). 138 samples had a collection-centrif-
ugation interval shorter than 60 minutes (min), 100 
samples an interval between 60 and 120 min, 77 
samples between 121 and 180 min and 60 samples 
had a collection-centrifugation interval longer 
than 180 min. Since the recommended treatment 
of blood samples according to ADA-NACB guide-
lines cannot be performed in most Italian labora-
tories, in this multi-centre study the FC-Mixture 
tube, containing citrate buffer, was established to 
be the reference tube for an accurate glucose de-
termination (8).
Methods
Glucose determinations in all plasma samples (FC-
Mixture, LH and FH) of the same volunteer were 
performed in a single analytical run, according to 
the instruments’ recommendations used in each 
laboratory: Cobas 6000, Cobas Integra, C702, C501 
and Hitachi 912 (Roche Diagnostics, Monza, Italy); 
ADVIA 2400 and Dimension Vista 1500 (Siemens 
Healthcare Diagnostics, Milan, Italy); Unicel DxC 
600i and AU5800 (Beckman Coulter, Milan, Italy); 
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Vitros fusion (Ortho Clinical Diagnostics, Milan, Ita-
ly). All the above-mentioned instruments use the 
hexokinase enzymatic method, with the exception 
of dry chemistry in Vitros system which uses the 
glucose oxidase method. The mean coefficient of 
variation (CV) of participating laboratories was 1.5 
± 0.34%. 
Statistical analysis
Continuous variables were tested for normality by 
the Kolmogorov–Smirnov test and are expressed 
as mean ± standard deviation (SD) if normally dis-
tributed or as median and interquartile range (IQR) 
if not normally distributed, respectively (13). Re-
peated measures ANOVA and pair-wise compari-
son using Bonferroni correction or Friedman test 
were used to test the difference between glucose 
concentrations in FH, FC-Mixture and LH tubes and 
the gold standard treatment according to ADA – 
NACB guidelines in the experimental study and to 
test the difference between glucose concentration 
in FH, LH and FC-Mixture tubes in the multi-centre 
study; as well as to test differences in serial glucose 
measurements performed after 1, 2 and 4 hours 
storage at RT in the experimental study. If P of 
ANOVA was significant, a post-hoc comparison was 
made using the paired t-Student test.
In the experimental study bias from reference glu-
cose was calculated as:
B = [ ( Gluval / Gluref ) x 100 ] - 100
where Gluval represents glucose concentration 
(mean of triplicate measurements) in FH and FC-
Mixture tubes and Gluref represents glucose con-
centration (mean of triplicate measurements) in 
the reference tube (LH with gold standard treat-
ment according ADA – NACB guidelines).
In the multicentric study bias from reference glu-
cose was calculated as:
B = [ ( Gluval / GluFCMix) x 100 ] - 100
where Gluval represents glucose concentration in 
LH and FH tubes while GluFCMIX represents glucose 
concentration in real life reference tube (FC-Mix-
ture, according ADA – NACB guidelines).
The acceptance criteria for bias and for total allow-
able error (TEa) were defined according biological 
variation studies (14) (desirable bias ≤ 1.8%, opti-
mal bias ≤ 0.92% and TEa ≤ 4.0%). Total allowable 
error (TEa) limits were defined using the following 
equation:
TEa = Biasdes + 1.96 + ( CVdes / RADsq3 )
where Biasdes is the desirable bias according bio-
logical variability (1.8%) and CVdes is the desirable 
imprecision according biological variability (2.3%) 
and RADsq3 is the correction of imprecision for 
triplicate measurements, that is TEa of 4.0%.
In the experimental project Bland-Altman analysis 
was used to assess the agreement between glu-
cose concentrations in FH, FC-Mixture and in refer-
ence LH tubes with ADA-NACB gold standard 
treatment. 
P-values < 0.05 were considered statistically signif-
icant. Statistical analysis was performed using the 
MedCalc statistical software version 15.11.0 (Med-
Calc, Ostend, Belgium).
Results
Experimental project
Mean plasma glucose concentration measured in 
100 LH sample tubes treated according the ADA - 
NACB guidelines was 5.47 ± 0.65 mmol/L. Mean 
plasma glucose concentration in FH sample tubes 
was 5.14 ± 0.66 mmol/L, 5.05 ± 0.65 mmol/L and 
5.00 ± 0.65 mmol/L, with a mean relative bias of 
-6.04%, -7.84% and -8.76%, exceeding the analyti-
cal goal for desirable bias based on biological vari-
ation criteria (≤ 1.8%) after 1, 2 and 4 h at RT, re-
spectively. Mean plasma glucose concentration in 
FC-Mixture tubes was 5.48 ± 0.65 mmol/L, 5.46 ± 
0.65 mmol/L and 5.46 ± 0.64 mmol/L with a mean 
absolute bias 0.20%, -0.10% and -0.22%, reaching 
the optimal analytical goal for bias based on bio-
logical variation criteria (≤ 0.92%) after 1, 2 and 4 h 
at RT, respectively. The ANOVA has shown statisti-
cally significant differences between glucose con-
centrations in LH, FH and FC-Mixture tubes (P < 
0.001). Pair-wise comparisons showed that glucose 
concentrations in FH tubes after 1, 2 and 4 h at RT 
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Figure 1. Comparison of glucose concentrations in sample tubes evaluated, stored at room temperature, with reference glucose 
concentrations using Bland-Altman plots. Reference glucose concentrations were obtained from lithium-heparin tubes placed in ice-
water slurry and centrifuged within 30 minutes, according to ADA-NACB guidelines. 
A – Comparison of reference glucose with sodium fluoride-sodium heparin (FH) glucose stored for 1 hour. B -  Comparison of refer-
ence glucose with FH glucose stored for 2 hours. C - Comparison of reference glucose with FH glucose stored for 4 hours. D - Com-
parison of reference glucose with sodium fluoride-citrate buffer-sodium EDTA (FC-Mixture) glucose stored for 1 hour. E - Comparison 
of reference glucose with FC-Mixture glucose stored for 2 hours. F - Comparison of reference glucose with FC-Mixture glucose stored 
for 4 hours.  Solid line (mean) – mean difference. Dashed lines (SD) – standard deviation. Dotted line – line of equality.
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were significantly lower than glucose in LH tubes 
treated according to ADA-NACB (P < 0.001). Con-
trarily, no statistically significant differences were 
observed in glucose concentrations comparing 
FC-Mixture and LH samples after 1 h (P = 0.499), 2 
h (P = 0.614) and 4 h storage at RT (P = 0.283). Fig-
ure 1 shows the Bland-Altman plot of glucose in 
FH, FC-Mixture tubes compared to reference glu-
cose in LH tubes treated according to ADA-NACB. 
Finally, 89.7% of FC-Mixture samples and 9.3% of 
FH samples were within the desirable TEa limits 
derived from biological variation data.
Multi-centre study
Results from the multi-centre study, mimicking 
real life conditions, were divided in four different 
groups according to time between blood collec-
tion and centrifugation, for data analysis purposes.
There were statistically significant differences (P < 
0.001) between median glucose (IQR) in LH tubes 
and FH tubes compared to paired reference glu-
cose in FC-Mixture tubes, regardless of the interval 
between blood collection and centrifugation: for 
intervals of ≤ 60 min: LH 5.49 (5.27 - 5.66) mmol/L, 
FH 5.55 (5.32 - 5.71) mmol/L vs. FC-Mixture 5.77 
(5.55 - 5.93) mmol/L. For the blood collection to 
centrifugation time interval of 61 - 120 min, medi-
an plasma glucose was 5.10 (4.93 - 5.21) mmol/L in 
LH tubes, 5.21 (5.05 - 5.32) mmol/L in FH tubes and 
5.60 (5.47 - 5.73) mmol/L in FC-Mixture tubes. For 
the time interval of 121-180 min, median plasma 
glucose was 4.71 (4.63 - 4.88) mmol/L in LH tubes, 
5.05 (4.88 - 5.21) mmol/L in FH tubes and 5.49 
(5.43-5.77) mmol/L in FC-Mixture tubes. After 180 
min median plasma glucose was 5.43 (4.98 - 5.83) 
mmol/L in LH tubes, 5.68 (5.43 - 6.27) mmol/L in 
FH tubes and 6.02 (5.87 - 6.82) mmol/L in FC-Mix-
ture tubes. Data of glucose stored at room tem-
perature at different time between blood drawing 
and centrifugation are summarized in Figure 2.
Mean bias respect to FC-Mixture tubes in FH tubes 
was -4.9%, -6.8%, -8.0% and -6.4% at ≤ 60 min, 61-
120 min, 121-180 min and > 180 min (P < 0.001), re-
spectively. Plasma glucose in LH tubes showed a 
lower bias (P < 0.001): -5.7%, -9.2%, -13.8% and 
-16% when samples were stored at room tempera-
ture for ≤ 60 min, 61-120 min, 121-180 min, and 181 
min or more, respectively. 
Discussion 
Plasma glucose concentrations measured in NaF/
Na2 heparin tubes stored at RT up to 4 h were low-
er than glucose in LH sample tubes placed in an 
ice-water slurry immediately after blood drawing 
and centrifuged at 2000 x g 15 min at 4 °C with 
plasma separated within 30 min (according to the 
ADA-NACB guidelines) (8). On the contrary, in FC-
mixture tubes, containing not only NaF but also 
citrate buffer and Na2EDTA, glucose concentration 
was preserved up to 4h at RT. 
This result can be explained by the fact that NaF 
exerts a particular inhibiting action on enolase, an 
enzyme involved in the final phase of the glycolyt-
ic process and, therefore, its action of inhibition of 
the glycolysis occurs quite late, approximately 1-2 
hours from blood collection (15). Accordingly, 
blood glucose measured in the NaF/Na2-heparin 
containing tubes, stored at RT for 4 hours, was 
lower compared to glucose measured in the same 
tubes stored for 2 hours. Furthermore, both were 
significantly lower than glucose in the same tubes 
stored at RT and centrifuged after 1 hour. As previ-
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ously reported (15,16), our results confirm that NaF 
blocks the glycolysis in a later stage.
On the other hand, as observed by Gambino et al. 
(10), FC-Mixture tubes allow maintaining a glucose 
concentration which matches the one obtained 
with the reference procedure, even after 4 hours 
of RT storage. The glycemia reduction in the NaF/
Na2 heparin samples, kept at RT for 2 hours, result-
ed be superior to the that observed by Gambino 
(7.8% compared to 4.5% after 2 hours at 37 °C) (10) 
as well as by Fobker (3.6% after 2 hours at RT) (17).
The novelty of our study was to test in real life rou-
tine of 15 different Italian laboratories, several con-
ditions of storage and time from blood drawing to 
centrifugation of the commonly used tubes for 
glucose determination (i.e. lithium-heparin and 
sodium-fluoride). Moreover, since the majority of 
laboratories can’t routinely implement the ADA-
NACB recommendations, our multi-centre study 
evaluated the effect on glucose determination of 
using an immediate glycolysis inhibitor such as cit-
rate buffer (10,17-19), i.e. Terumo FC-Mixture, com-
pared to the most commonly used LH and FH 
tubes.
The underestimation of glucose in the LH and FH 
tubes resulted to be statistically significant already 
in the group of tubes centrifuged within 60 min-
utes from blood collection and the bias increased 
with the longer time intervals. In the LH tubes the 
average bias tends to increase almost linearly with 
time (from -5.7% in the samples centrifuged within 
60 min to -16% in those centrifuged after more 
than 180 min), whereas in the FH tubes, as expect-
ed, the glycaemia decrease stops after two hours 
of storage. 
Therefore, in accordance to the pilot-study, the 
multi-centre experience confirms that the NaF 
alone does not allow an immediate glycolysis inhi-
bition. We suggest that FC-Mixture should be used 
exclusively for glucose determination, because all 
the centres involved in the study noticed the pres-
ence of a higher level of haemolysis compared 
with the LH and FH tubes. 
The haemolysis can be attributed to the high acid-
ity of the additive present in the FC mixture tubes. 
The evaluation of serum indexes was not intended 
in our study. However, since some laboratories had 
the possibility to resume their data on haemolysis 
index, in 395 of 1125 FC-Mixture samples tubes it 
was possible to verify the haemolysis index, show-
ing that 99% of the tubes had a concentrations of 
free haemoglobin < 2.0 g/L. As previously report-
ed at this haemoglobin concentration, no analyti-
cal interference has been observed in glucose de-
termination (20).
Over the course of the time the laboratories im-
proved the analytical performances in the glucose 
determination. However, the reduction of glucose 
in vitro under the effect of glycolysis is quantita-
tively relevant and can invalidate the accuracy of 
the results. An accurate determination of glucose 
is therefore fundamental for the diagnosis of DM 
and particularly GDM, when HbA1c cannot substi-
tute the determination of plasma glucose for the 
diagnosis (1,2,21). If the organization of the labora-
tory does not allow a quick centrifugation of the 
tube, it is necessary to use a tube containing glyc-
olysis inhibitors (8). However, the use of NaF alone 
does not allow an immediate glycolysis blockage 
(7-9). In the epidemiologic studies that defined the 
cut-offs for the diagnosis of DM, IFG or IGT, tubes 
containing the NaF as an inhibitor were employed 
(5,8). Over the course of those studies, no waiting 
times have been specified before the separation 
of the plasma from the blood cells in which the 
glucose was reduced under the effect of the glyco-
lysis, probably leading to an underestimation in 
the predominance of the diabetes.
In the light of the present and recently published 
results (17,22-24), it might emerge the impellent 
need of undertaking new standardized and pre-
analytically well-performed studies using FC-mix-
ture tubes with the aim of redefining DM cut-offs. 
The use of acidified tubes could bring to an in-
crease of the average glucose value of the popula-
tion, as it was highlighted in recent studies (25,26).
In conclusion, the authors of the present study 
agree on the fact that, following a good laboratory 
practice, in order to do a correct diagnosis of DM, 
and above all of GDM, trying to avoid wrong clas-
sifications of patients, the use of an immediate in-
http://dx.doi.org/10.11613/BM.2016.006 Biochemia Medica 2016;26(1):68–76 
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hibitor of the glycolysis has to be regarded as nec-
essary (27). The FC mixture in Terumo Venosafe 
Glycemia tubes (10,17,22), from the data presented 
seem to be suitable for this purpose, while NaF 
alone is not. 
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